Race appoints clinical and FDA regulatory strategy advisor
Race appoints clinical and FDA regulatory strategy advisor
Race Oncology is pleased to announce that it has appointed the clinical and regulatory strategy advisor, CCS Associates (CCSA, California, USA) to advise on development options for Bisantrene as an inhibitor of the Fat...
2020 Annual Report Summary
2020 Annual Report Summary
Dear Shareholders It is my pleasure to formally open the annual report to Race Oncology Shareholders for the period ended 30 June 2020. It’s been a highly successful year as regards progress in reframing...
Changing of the guard at Race
Changing of the guard at Race
The Board of Directors of Race Oncology wishes to advise that Dr. Peter Molloy has decided to step down as Managing Director and Chief Executive Officer. Chairman Dr John Cullity, and Chief Scientific Officer...
Race Oncology 2019 Annual General Meeting Presentation
Race Oncology 2019 Annual General Meeting Presentation
Overview of Race Oncology’s new “5 path” strategy for the development of Bisantrene. • Introduction & Welcome | Mr Peter Molloy CEO/MD (0.00 – 10.00) • Race’s 5 Path Strategy | Dr Daniel Tillett...
Dr Daniel Tillett joins Race Board
Dr Daniel Tillett joins Race Board
17 September 2019 – Race Oncology Limited (ASX: RAC) is pleased to announce that prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has today joined the Board of Directors of Race Oncology Ltd....
